CA – 91748, Los Angeles -- (SBWire) -- 07/18/2019 --Typically used as anticancer drugs, tyrosine kinase inhibitors, as the name suggests, inhibit tyrosine kinase enzymes that take the responsibility of the activation of several proteins by signal transduction cascades. A number of tyrosine kinase inhibitors have been proven to be effective as anti-leukemic and anti-tumor agents. Increasing investment in research and development activities is expected to set the tone for strong growth of the global tyrosine kinase inhibitors market. In May 2019, it was announced in a press release that the results of the phase 3 study of the Kit-PDGFR? kinase inhibitor ripretinib of Deciphera Pharmaceuticals, a US clinical-stage biopharmaceutical company, are ready to come out mid-2019.
The report offers useful guidelines for new as well as established companies to increase their sales and achieve a position of strength in the global tyrosine kinase inhibitors market.
Market Dynamics
Increasing application of tyrosine kinase inhibitors in the treatment of different types of cancer is expected to fuel the growth of the global market. The demand for tyrosine kinase inhibitors is predicted to improve with the growing prevalence of cancer around the globe. Moreover, tyrosine kinase inhibitors offer great advantages over radiotherapy and chemotherapy and have impressive efficacy and specificity. In addition, increasing awareness about cancer and its treatment in developing countries, unmet medical needs, and availability of pipeline tyrosine kinase inhibitors are anticipated to put a positive impact on the global market.
However, the expensive cost of tyrosine kinase inhibitors is prophesied to hamper the global market growth to some extent.
Get PDF template of this report: https://www.qyrconsulting.com/request-sample/13
Market Segmentation
By Process
? BCR-ABL TKIs
? Vascular Endothelial Growth Factor (VEGFR) TKIs
? Epidermal Growth Factor Receptor (EGFR) TKIs
? Other TKIs
By Application
? Chronic Myeloid Leukemia (CML)
? Lung Cancer
? Renal Cell Cancer
? Breast Cancer
By Distribution Channel
? Hospital Pharmacies
? Online Pharmacies
? Independent Pharmacies
North America is prognosticated to collect a leading share of the global tyrosine kinase inhibitors market owing to high healthcare expenditure. Other factors such as high demand for targeted therapies and other advanced treatments are foreseen to further increase North America's share of the global market. Analysts predict Asia Pacific to have a high attractiveness index because of the rising prevalence of lung cancer in China and India. Other Asia Pacific countries such as Australia and Japan show high adoption of digital healthcare technology and availability of well-established medical facilities.
Key Players
Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., , Eisai Co., Ltd., and Eurofarma Laboratórios S/A are some of the prominent names of the global tyrosine kinase inhibitors market covered in the research study.
Report TOC, Figures and Tables:
Table of Contents
Overview of the Report: The report starts with research scope, major players studied by the authors, years considered for the research study, objectives of the study, and analysis of market share by application and market size growth rate by type.
Global Growth Trends: Here, the size of the global Bio-pharma market is studied along with sales and revenue analysis. This section also includes industry trends and analysis of the growth rate of the global Bio-pharma market by region.
Regional Analysis: All of the regions and countries analyzed in the report are studied on the basis of revenue, sales, and share in the global Bio-pharma market.
Company Profiles: Almost all leading companies operating in the global Bio-pharma market are profiled in this section, taking into account their recent developments, market share, and other vital factors.
Market Forecast: Apart from revenue and sales forecast of the global Bio-pharma market, this section provides forecast of all
About QYR Consulting
We established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.
Tyrosine Kinase Inhibitors Market Companies Investing in Product Development to Remain Ahead of the Curve 2019–2025
The Tyrosine Kinase Inhibitors Market research study stipulates a clear overview of the current market including the past and the projected future of market size concerning volume, technological advances, and economic elements in the market industry.